Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GP2013 vs MabThera with CVP in previously untreated advanced follicular lymphoma
NL-OMON44911Phase 3Active, not recruiting
- Sponsor
- Sandoz
- Start
- Feb 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rituximab in follicular lymphoma (FL) (2 arms), sponsored by Sandoz. Primary endpoint: Overall response rate. Started Feb 2012; status: active, not recruiting.
02
Drugs
rituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NL-OMON44911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44911.